期刊文献+

奥曲肽联合特利加压素治疗肝硬化疗效及对患者肝静脉压力梯度影响的观察 被引量:4

Research on the effects of the combination of octreotide and terlipressin on hepatic venous pressure gradient in cirrhotic patients
下载PDF
导出
摘要 目的:评价奥曲肽联合特利加压素治疗肝硬化的疗效及对患者肝静脉压力梯度的影响,探讨其临床适用性。方法:选择68例肝硬化合并静脉曲张破裂出血患者,将其随机分为观察组与对照组,每组34例,对照组予奥曲肽静脉给药治疗,观察组予奥曲肽联合特利加压素静脉给药治疗。观察两组用药前及治疗1 min、5 min、10 min、15 min、25 min以及35 min后患者的肝静脉锲入压(WHVP)、肝静脉游离压(FHVP)和肝静脉压力梯度(HVPG)指标的变化情况。结果:1治疗1 min后,两组患者的WHVP均显著升高,差异有统计学意义(t=0.6868,P<0.05),观察组治疗25 min后WHVP指标均显著高于对照组,差异有统计学意义(t=2.0877,P<0.05);2治疗1 min后两组患者的FHVP均显著升高,差异有统计学意义(t=0.9159,P<0.05)。观察组患者在25 min后FHVP指标均显著高于对照组患者,差异均有统计学意义(t=2.0570,P<0.05)。观察组患者在25 min后HVPG高于对照组,差异有统计学意义(t=5.4954,P<0.05)。结论:奥曲肽给药后,联合特利加压素可显著降低肝静脉压力梯度的力度,起到更好的降低门静脉压力作用,适合临床推广应用。 Objective:To evaluate the effects of the combination of octreotide and terlipressin on hepatic venous pressure gradient in cirrhotic patients, and to explore its clinical applicability.Methods: 68 acute variceal bleeding in cirrhotic patients were selected from January 2012 to January 2015, and they were simple randomly divided into the control group and the experimental, 34 cases in each group, and the control group were only given octreotide, while the experimental group were given the combination of octreotide, and measured the WHVP, FHVP, HVPG before drugs and at 1min, 5min,10min,15 min,25 min,35 min.Results:1)After 1min treatment the two groups of patients with WHVP were significantly higher(t=0.6868,P〈0.05), And WHVP in the test group patients after 25min were significantly higher than those of patients in the control group, the difference was statistically significant (t=2.0877,P〈0.05). 2)After 1min treatment the two groups of patients with FHVP were significantly higher, the differences were statistically significant (t=0.9159,P〈0.05), And the test group patients in 25min after FHVP were significantly higher than those of patients in the control group, the difference was statistically significant (t=2.0570,P〈0.05). After 1min treatment the two groups of patients with HVPG were significantly higher, the differences were statistically significant (t=5.4954,P〈0.05).Conclusions: Octreotide administration, combined with terlipressin can significantly reduce the hepatic venous pressure gradient force, play a better function of decreasing portal vein pressure, suitable for long-term clinical application.
出处 《中国医学装备》 2015年第9期92-95,共4页 China Medical Equipment
关键词 奥曲肽 特利加压素 食管胃静脉曲张破裂出血 肝静脉压力梯度 Octreotide Terlipressin Esophageal gastric variceal bleeding Hepatic venous pressure gradient
  • 相关文献

参考文献12

二级参考文献49

共引文献62

同被引文献38

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部